NAMS NewAmsterdam Pharma Company N.V.
Healthcare$36.11+1.89%ClosedMarket Cap: $4.22B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
6.45
P/S
183.61
EV/EBITDA
-15.90
DCF Value
$3.54
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.5%
Operating Margin
-953.6%
Net Margin
-942.8%
ROE
-29.8%
ROA
-29.0%
ROIC
-32.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $3.0M | 83.6% | $-58.4M | $-48.4M | $— | — |
| Q4 null | $32.0K | -84.4% | $-66.0M | $-74.9M | $— | — |
| FY null | $22.5M | 99.7% | $-225.7M | $-203.8M | $— | — |
| Q3 null | $348.0K | 100.0% | $-55.1M | $-72.0M | $— | — |
| Q2 null | $19.1M | 100.0% | $-35.6M | $-17.4M | $— | — |
| Q1 null | $3.0M | 100.0% | $-68.9M | $-39.5M | $— | — |
| Q4 null | $12.8M | 100.0% | $-43.2M | $-92.2M | $— | — |
| FY null | $45.6M | 100.0% | $-176.3M | $-241.6M | $— | — |
| Q3 null | $29.1M | 100.0% | $-25.0M | $-16.6M | $— | — |
| Q2 null | $2.3M | 100.0% | $-52.6M | $-39.0M | $— | — |
| Q1 null | $1.4M | 100.0% | $-55.5M | $-93.8M | $— | — |
| Q4 2023 | $803.0K | 100.0% | $-51.1M | $-49.5M | $-0.52 | — |